My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

29.43 +0.21 (+0.74%)

Streaming Delayed Price Updated: 12:33 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Arcutis Biotherapeutics (NASDAQ:ARQT) Combines High-Growth Momentum with Bullish Technical Setup ↗

December 30, 2025

Arcutis Biotherapeutics (ARQT) combines strong revenue growth & earnings momentum with a bullish technical chart setup, signaling a potential breakout opportunity.

Via Chartmill

Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares ↗

December 23, 2025

Even after cutting back, this remains the fund’s largest bet and the timing lines up with a pivotal stretch for Arcutis’ pipeline.

Via The Motley Fool

Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears ↗

December 23, 2025

When a clinical-stage biotech is sitting on nearly $600 million in cash and lining up an FDA filing, sharp investors stop arguing about the past rally and start debating what comes next.

Via The Motley Fool

Topics Regulatory Compliance

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Via MarketMinute

Topics ETFs Economy Intellectual Property

This Biotech Stock Could Cure Your Portfolio's Pain ↗

December 14, 2025

A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's peak sales estimations makes this biotech stock attractive.

Via The Motley Fool

ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Shows Strong Technical and Fundamental Momentum ↗

December 11, 2025

Arcuitis Biotherapeutics (ARQT) exemplifies a high-growth momentum stock in a confirmed technical uptrend, blending strong fundamentals with a robust price structure.

Via Chartmill

Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

December 08, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Why Shares in Arcutis Biotherapeutics Surged Again This Week ↗

November 21, 2025

The company continues to receive good news from the Food and Drug Administration.

Via The Motley Fool

Earnings Scheduled For October 28, 2025 ↗

October 28, 2025

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

November 17, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Peering Into Arcutis Biotherapeutics Inc's Recent Short Interest ↗

November 13, 2025

Via Benzinga

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

November 13, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Strong Trend with High-Growth Momentum ↗

November 10, 2025

ARQT stock combines a strong Minervini Trend Template setup with explosive sales and earnings growth, creating a compelling high-growth momentum opportunity.

Via Chartmill

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology

November 04, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments

October 30, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

October 30, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

These stocks are moving in today's session ↗

October 28, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Arcutis Q3 2025 Earnings Call Transcript ↗

October 28, 2025

Arcutis Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Top stock movements in today's session. ↗

October 28, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 28, 2025

Via Benzinga

Crude Oil Falls Over 2%; PayPal Shares Spike Higher ↗

October 28, 2025

Via Benzinga

Here's Why This Biotherapeutics Company's Stock Surged Higher by 30% Today ↗

October 28, 2025

Arcutis Biotherapeutics had an excellent update for investors and its future looks bright.

Via The Motley Fool

Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise. ↗

October 28, 2025

Arcutis Biotherapeutics smashed quarterly calls Tuesday and reported its first-ever positive net income.

Via Investor's Business Daily

Traders are paying attention to the gapping stocks in Tuesday's session. ↗

October 28, 2025

Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

October 28, 2025

Via Benzinga

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Reports Strong Q3 2025 Earnings Beat and Return to Profitability ↗

October 28, 2025

Arcutis (ARQT) Q3 2025 earnings crush estimates with a surprise profit. Revenue of $99.2M beats forecasts, driving the stock up 16% on strong ZORYVE demand.

Via Chartmill

Topics Earnings

Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results

October 28, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Uncovering Potential: Arcutis Biotherapeutics's Earnings Preview ↗

October 27, 2025

Via Benzinga

Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference

October 24, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.